← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › PROTEIN KINASE INHIBITORS › Other protein kinase inhibitors
quizartinib
L01EX11
Forms & Strengths
- Oral tablets: 17.7 mg
- Oral tablets: 26.5 mg
Adult Dosing
- Newly diagnosed FLT3-ITD positive AML: Induction 35.3 mg orally once daily on Days 8-21 of cycle 1, and on Days 8-15 of cycle 2 with cytarabine and anthracycline
- Consolidation: 35.3 mg orally once daily on Days 8-21 with high-dose cytarabine
- Maintenance: 26.5 mg to 53.5 mg orally once daily for up to 36 cycles
Pediatric Dosing
- Safety and efficacy have not been established in pediatric patients
Indications
- Treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy
Mechanism of Action
- Small molecule kinase inhibitor that targets FLT3 (FMS-like tyrosine kinase 3)
- Inhibits FLT3 receptor autophosphorylation, leading to disruption of FLT3 receptor-mediated signaling and inhibition of proliferation of leukemic cells expressing FLT3-ITD mutations
- Also inhibits KIT, CSF1R, PDGFRA, PDGFRB, and RET kinases
Contraindications
- Hypersensitivity to quizartinib or any of its excipients
- Moderate to severe pre-existing QT interval prolongation (QTcF > 450 ms before treatment initiation)
Adverse Reactions
- QT prolongation
- Torsades de pointes
- Myelosuppression (febrile neutropenia, thrombocytopenia, anemia)
- Infections
- Nausea and vomiting
- Abdominal pain
- Diarrhea
- Edema
- Headache
- Hypertension
- Elevated transaminases and gamma-glutamyl transferase
Drug Interactions
- Strong CYP3A inhibitors: May increase quizartinib exposure and risk of QT prolongation; avoid coadministration
- Strong or moderate CYP3A inducers: May decrease quizartinib exposure; avoid coadministration
- QT interval-prolonging drugs: Concomitant use increases the risk of QT prolongation and ventricular arrhythmias; avoid coadministration
Curated Content: Needs Vetting Before Put to Clinical Use